Probiotics

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Recent probiotic research has been most intensively studied in (i) cystic fibrosis (CF), focusing on modulation of gut dysbiosis/inflammation and downstream respiratory outcomes, and (ii) metabolic conditions in pregnancy (prevention of gestational diabetes mellitus, GDM). In CF, multiple randomized controlled trials and two recent evidence syntheses (including a Cochrane review) have evaluated single-strain and multistrain probiotics as well as synbiotics, with outcomes spanning pulmonary exacerbations, lung function (FEV1), hospitalizations, quality of life, and intestinal inflammatory biomarkers (notably fecal calprotectin and cytokines such as IL-6/IL-8). In pregnancy, meta-analytic evidence has examined probiotics as a preventive strategy for GDM across diverse populations and study designs, with subgroup analyses exploring effect modification by maternal BMI and age. Smaller RCTs also extend into diabetes-related complications (e.g., diabetic retinopathy), typically emphasizing metabolic and inflammatory profiles over longer-term clinical endpoints.

The strongest evidence from the studies reviewed here supports a modest anti-inflammatory effect in CF, particularly reductions in fecal calprotectin, although the certainty is low and the clinical significance remains unclear. Across CF trials, pooled results do not show consistent improvements in key clinical outcomes such as FEV1, hospitalization rates, or quality of life, and effects on pulmonary exacerbations are either non-significant or uncertain with confidence intervals compatible with benefit or no effect. Safety signals in CF appear uncommon but incompletely captured; reported adverse events are rare (e.g., isolated gastrointestinal symptoms and a severe allergic reaction in one terminated trial), and several trials did not prospectively report adverse events. For GDM prevention, meta-analysis suggests probiotics may reduce incident GDM overall, but with substantial heterogeneity and evidence that benefit may be concentrated in subgroups (e.g., younger women and those with lower BMI), indicating that effects may depend on baseline risk and host factors.

Key areas needing more research include adequately powered, multicenter RCTs with longer follow-up (≥12 months in CF) and standardized reporting of probiotic strain(s), dose, viability, and adherence, as well as harmonized outcome definitions (especially for pulmonary exacerbations) and systematic adverse-event surveillance. In CF specifically, studies should clarify whether biomarker changes (e.g., calprotectin, cytokines) translate into meaningful clinical benefits and identify which patient subgroups (age, baseline dysbiosis/inflammation, antibiotic exposure) might respond. In GDM prevention, future work should address sources of heterogeneity (strain/formulation, timing and duration of supplementation, baseline metabolic risk), confirm subgroup findings prospectively, and prioritize clinically important maternal and neonatal outcomes beyond GDM incidence. Across indications, mechanistic studies linking microbiome changes to host immune/metabolic endpoints would strengthen causal inference and guide targeted probiotic or synbiotic selection.

1. What conditions has Probiotics been studied for?

  • Cystic fibrosis (CF): Multiple randomized controlled trials (RCTs) and systematic reviews/meta-analyses evaluated probiotics and synbiotics for pulmonary outcomes (exacerbations, FEV1, hospitalizations), gastrointestinal inflammation (e.g., fecal calprotectin), quality of life, and safety.

  • Gestational diabetes mellitus (GDM) prevention: Meta-analysis of RCTs in pregnant women assessed whether probiotics reduce the incidence of GDM.

  • Diabetic retinopathy (DR): A double-blind, placebo-controlled RCT tested probiotics for effects on metabolic markers (insulin, insulin resistance, HbA1c) and clinical symptoms.

  • Hair thinning / alopecia:

    • Thinning hair (topical): Double-blind placebo-controlled trial of a lotion containing Lactiplantibacillus plantarum subsp. plantarum N793.

    • Androgenic alopecia (AGA) (oral): Double-blind parallel-group trial of a multi-strain Lactiplantibacillus probiotic mixture.

  • Insomnia: A meta-analysis of RCTs evaluated probiotics’ effects on sleep quality and mood in insomnia (abstract provided is truncated, so details of results are not available here).

2. Does it work in treating those conditions? Summarize the evidence.

  • Cystic fibrosis (CF): mixed/inconsistent clinical benefit; possible anti-inflammatory effect.

    • Pulmonary exacerbations: A Cochrane review (12 RCTs; 464 participants) found probiotics may reduce exacerbations over 4–12 months, but the estimate was imprecise (MD −0.32 episodes/person; 95% CI −0.68 to 0.03; P=0.07; low-certainty). A newer meta-analysis (13 RCTs; n=552) found no significant reduction (RR 0.81; 95% CI 0.48–1.37; p=0.43).

    • Lung function (FEV1): No meaningful improvement in the Cochrane review (MD 1.36% predicted; 95% CI −1.20 to 3.91; low-certainty). The 2000–2024 meta-analysis also found no significant improvement (MD 4.7; 95% CI −5.4 to 14.8; p=0.37).

    • Hospitalizations / quality of life: No clear benefit in pooled analyses for hospitalizations (Cochrane: MD −0.44 admissions/person; 95% CI −1.41 to 0.54; low-certainty). The 2000–2024 meta-analysis similarly reported no significant differences in hospitalizations or quality of life overall.

    • Intestinal inflammation: Evidence suggests reduction in fecal calprotectin (Cochrane pooled MD −47.4 µg/g; 95% CI −93.28 to −1.54; P=0.04; low-certainty). The 2000–2024 meta-analysis also notes reductions in fecal calprotectin and some pro-inflammatory interleukins (e.g., IL-6, IL-8) in several studies.

    • Growth/nutrition: No evidence of benefit on height/weight/BMI in two trials (low-certainty).

  • Gestational diabetes mellitus (GDM) prevention: modest benefit overall, with important subgroup differences and heterogeneity.

    • Meta-analysis of 14 RCTs (n=3527) found probiotics reduced GDM incidence vs control (RR 0.71; 95% CI 0.52–0.96; P=0.03), but with substantial heterogeneity (I2=73%).

    • Effect modification was reported: benefit was seen in women with BMI < 26 kg/m2 but not BMI ≥ 26 kg/m2 (subgroup difference P=0.001), and in women < 30 years but not ≥ 30 years (subgroup difference P<0.001). These are subgroup findings and may not generalize.

  • Diabetic retinopathy (DR): improves some glycemic/insulin-resistance markers; no clear symptom benefit.

    • In a 12-week double-blind RCT (completed n=55), probiotics significantly improved insulin (−4.9 ± 6.5 vs +3.0 ± 7.7 µIU/mL; P<0.001), HOMA-IR (−2.5 ± 3.8 vs +1.1 ± 2.7; P<0.001), HbA1c (−0.4 ± 0.7 vs −0.02 ± 0.2%; P=0.01), and QUICKI (+0.02 ± 0.03 vs −0.03 ± 0.04; P<0.001) versus placebo.

    • No significant effect was reported on other metabolic profiles or clinical symptoms.

    • Limitations include small sample size and attrition (72 randomized; 55 completed), and short duration (12 weeks).

  • Hair thinning / alopecia: early and condition-specific signals; not consistently positive.

    • Topical N793 for thinning hair (24 weeks; n=104): No difference in hair density in the full analysis; a subgroup with “relatively mild progression” showed significantly better hair density with N793 than placebo. Subgroup-only benefit increases uncertainty.

    • Oral multi-strain Lactiplantibacillus for AGA (16 weeks; 115 completers): Significant decline in telogen hairs in the probiotic group (p<0.05) and hair thickness decreased in placebo (p<0.05). Many other hair variables were not significantly changed. Some age-stratified findings (<37.5 years) were suggestive but not clearly statistically significant (p values around 0.07–0.09 for some outcomes). The probiotic group showed increased abundance of Lactobacillus and a shift toward more anagen hair.

  • Insomnia: evidence cannot be summarized from the provided text.

    • The study indicates a meta-analysis of RCTs assessing sleep quality and mood, but results are not included in the excerpt provided, so effectiveness cannot be concluded from these studies alone.

3. What health benefits does it have?

  • Reduced intestinal inflammation in CF: Probiotics reduced fecal calprotectin in pooled CF trial data (MD −47.4 µg/g; 95% CI −93.28 to −1.54; low-certainty), and some studies reported reductions in inflammatory cytokines (e.g., IL-6, IL-8) in the 2000–2024 meta-analysis.

  • Potential reduction in GDM risk (prevention): Overall reduced incidence in a meta-analysis (RR 0.71; 95% CI 0.52–0.96), with stronger effects reported in younger women and those with lower BMI (subgroup findings).

  • Improved glycemic/insulin-resistance markers in DR: In a 12-week RCT, probiotics improved insulin, HOMA-IR, HbA1c, and QUICKI versus placebo, though not broader metabolic markers or symptoms.

  • Possible hair-related benefits in select groups: Topical N793 showed benefit only in a subgroup with mild thinning progression; an oral Lactiplantibacillus mixture reduced telogen hairs and was associated with a more favorable anagen/telogen profile in AGA.

4. Does it have any downsides or side effects?

  • CF trials (Cochrane review): adverse events were uncommon but did occur.

    • Across trials that reported adverse events a priori, there was one severe allergic reaction (severe urticaria) in a terminated trial (12 participants; protocol only).

    • Two other trials reported single events: vomiting (one child) and diarrhea (one child).

    • The review estimated a number needed to harm (any adverse reaction, serious or not) of 52 people (low-certainty evidence). No deaths were reported.

    • Important limitation: many trials did not comprehensively pre-specify or report adverse events, so rare harms could be missed.

  • CF 2000–2024 meta-analysis: reported that none of the included studies documented serious adverse events associated with the intervention (as summarized by the authors).

  • AGA trial: the probiotic mixture was described as well tolerated, with 90% adherence; specific adverse event rates are not detailed in the study.

  • General evidence limitations: Effects and side effects are strain-, dose-, and population-dependent; the CF review explicitly notes variability in probiotic composition and dosage and calls for larger, longer RCTs.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report pharmacogenomic analyses (i.e., differential probiotic effects by human genotype) for any condition.

  • Cystic fibrosis is caused by CFTR mutations, but the CF probiotic trials and meta-analyses summarized here did not report outcomes stratified by CFTR genotype or other genetic variants. Therefore, no evidence-based conclusions can be made from these studies about which CFTR variants might benefit more or be at higher risk.

  • GDM, DR, alopecia, and insomnia studies: no genotype-stratified results are described.

Bottom line: based on these studies alone, there is no direct evidence that probiotics are specifically beneficial or harmful for particular genetic variants; any such claims would require dedicated genotype-stratified trials or analyses.

References

  1. Probiotics for people with cystic fibrosis
    Michael J Coffey, Millie Garg, Nusrat Homaira, Adam Jaffe, Chee Y Ooi (2020)
  2. Effectiveness of Probiotics, Prebiotics, and Symbiotic Supplementation in Cystic Fibrosis Patients: A Systematic Review and Meta-Analysis of Clinical Trials
    Freiser Eceomo Cruz Mosquera, Claudia Lorena Perlaza, Anisbed Naranjo Rojas, Saray Murillo Rios, Alejandra Carrero Gallego (2025)
  3. Probiotics for the prevention of gestational diabetes mellitus: A meta-analysis of randomized controlled trials
    Xue Li, Luwen Zhang, Yuanqi He, Dandan Zhang, Shihong Zhang (2024)
  4. The effects of probiotics supplements on metabolic indices and clinical signs in patients with diabetic retinopathy, a randomized double blind clinical trial
    Hasan Farajipour, Hamid Reza Matin, Zatollah Asemi, Saeed Sadr, Maryam Tajabadi-Ebrahimi (2024)
  5. Effect of applyingLactiplantibacillus plantarumsubsp.plantarumN793 to the scalps of men and women with thinning hair: a randomized, double-blind, placebo-controlled, parallel-group study
    Ayaka Mori-Ichioka, Yosuke Sunada, Takashi Koikeda, Hideo Matsuda, Shinji Matsuo (2024)
  6. Randomized Clinical Trial to Evaluate the Effect of Probiotic Intake on Androgenic Alopecia
    Alejandro García-Navarro, María Isabel Vasallo-Morillas, Roge Navarro-Belmonte, Cristina Vilanova, Daniel Torrent (2024)
  7. Impact of probiotics on sleep quality and mood states in patients with insomnia: a systematic review and meta-analysis
    Yi Liu, Yunfeng Yu, Shenghua Lu, Kang Tan, Pengfei Jiang (2025)
  8. Gaba-producing lactobacilli boost cognitive reactivity to negative mood without improving cognitive performance: A human Double-Blind Placebo-Controlled Cross-Over study
    Melania Casertano, Matthijs Dekker, Vincenzo Valentino, Francesca De Filippis, Vincenzo Fogliano (2024)
  9. The effect of probiotic consumption on lipid profile, glycemic index, inflammatory markers, and liver function in NAFLD patients: A systematic review and meta-analysis of randomized controlled trials
    Sadegh Mozaffari, Mahdeyeh Aliari, Solaleh Emamgholipour, Hossein Hosseini, Pedram Rezaei Amirkiasar (2024)
  10. The effect of gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review and network meta-analysis
    Yijia Song, Sutong Liu, Lihui Zhang, Wenxia Zhao, Yuanmei Qin (2025)
  11. Efficacy of probiotics in the treatment of oral mucositis in head and neck cancer patients: A systematic review and meta-analysis
    Peixin Lin, Jiafeng Zhuang, Jing Lai, Ji Cui, Danxian Jiang (2024)
  12. The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis
    Youhe Wu, Yuetong Li, Qi Zheng, Lanjuan Li (2024)
  13. The effect of probiotics on severe oral mucositis in cancer patients undergoing chemotherapy and/or radiotherapy: A meta-analysis
    ZhiYi Zhu, Wenting Pan, Xianqing Ming, Jiale Wu, Xinyue Zhang (2024)
  14. Oral probiotic supplementation to alleviate diarrhea induced by fluoropyrimidines or irinotecan-based chemotherapy: A systematic review and meta-analysis
    Tippawan Siritientong, Daylia Thet, Nattawut Leelakanok, Nutthada Areepium (2025)
  15. The impact of probiotics on core autism symptoms - A systematic review and meta-analysis of randomized clinical trials
    Maja Kotowska, Maciej Kołodziej, Hania Szajewska, Jan Łukasik (2024)
  16. Efficacy and safety ofBacteroides fragilisBF839 for pediatric autism spectrum disorder: a randomized clinical trial
    Chu-Hui Lin, Ting Zeng, Cui-Wei Lu, De-Yang Li, Yi-Ying Liu (2024)
  17. Probiotics for autism spectrum disorder: An updated systematic review and meta-analysis of effects on symptoms
    Saman Soleimanpour, Mohammad Abavisani, Alireza Khoshrou, Amirhossein Sahebkar (2024)
  18. The efficacy and safety of probiotics in the adjuvant treatment of psoriasis: a systematic review and meta-analysis of randomized controlled trials
    Yiran Zhu, Fan Xu, Hao Chen, Quanhui Zheng (2024)
  19. Effects of probiotic supplementation on testosterone levels in healthy ageing men: A 12-week double-blind, placebo-controlled randomized clinical trial
    Lennart Ljunggren, Eile Butler, Jakob Axelsson, Mikael Åström, Lars Ohlsson (2024)
  20. The effects of probiotic supplementation on cardiometabolic health in patients with prediabetes: a systematic review, meta-analysis, and GRADE assessment
    Rongfang Liu, Gao Wong (2025)


Related

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!